354 related articles for article (PubMed ID: 12107192)
1. Somatostatin analogs in acromegaly.
Freda PU
J Clin Endocrinol Metab; 2002 Jul; 87(7):3013-8. PubMed ID: 12107192
[No Abstract] [Full Text] [Related]
2. Distribution and functionality of the somatostatin receptor subtypes in acromegaly.
Saveanu A; Gunz G; Dufour H; Enjalbert A; Culler MD; Jaquet P
J Endocrinol Invest; 2003; 26(8 Suppl):4-7. PubMed ID: 15233203
[No Abstract] [Full Text] [Related]
3. Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits?
Chanson P
Eur J Endocrinol; 1997 Apr; 136(4):359-61. PubMed ID: 9150692
[No Abstract] [Full Text] [Related]
4. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
[TBL] [Abstract][Full Text] [Related]
5. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin agonists for treatment of acromegaly.
Ben-Shlomo A; Melmed S
Mol Cell Endocrinol; 2008 May; 286(1-2):192-8. PubMed ID: 18191325
[TBL] [Abstract][Full Text] [Related]
7. The future of somatostatin analogue therapy.
Stewart PM; James RA
Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Oct; 13(3):409-18. PubMed ID: 10909432
[TBL] [Abstract][Full Text] [Related]
8. [Somatostatin analogs in the clinical management of pituitary neoplasms].
Colao A; Dorato M; Pulcrano M; Rossi FW; Auriemma RS; Lombardi G; Lastoria S
Minerva Endocrinol; 2001 Sep; 26(3):181-91. PubMed ID: 11753242
[TBL] [Abstract][Full Text] [Related]
9. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
10. [Somatostatin analogs].
Krysiak R; Okopień B; Herman ZS
Pol Arch Med Wewn; 2006 Oct; 116(4):988-97. PubMed ID: 18416302
[No Abstract] [Full Text] [Related]
11. Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly.
Ben-Shlomo A; Melmed S
J Clin Endocrinol Metab; 2003 Mar; 88(3):963-8. PubMed ID: 12629068
[No Abstract] [Full Text] [Related]
12. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
[TBL] [Abstract][Full Text] [Related]
13. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
[TBL] [Abstract][Full Text] [Related]
14. The effects of somatostatin analogs on tumor shrinkage in acromegaly.
Pedroncelli AM; Montini M; Albizzi M; Barbò R; Pagani G
J Endocrinol Invest; 2003; 26(8 Suppl):50-4. PubMed ID: 15233213
[No Abstract] [Full Text] [Related]
15. Structure and function of somatostatin receptors in growth hormone control.
Shimon I; Melmed S
J Endocrinol; 1997 Oct; 155 Suppl 1():S3-6; discussion S7-8. PubMed ID: 9389989
[TBL] [Abstract][Full Text] [Related]
16. [Effect of lanreotide on prolactin level in patients with pituitary mixed tumors].
Wasko R; Sawicka J; Stachowiak C; Kozak W; Junik R; Sowinski J
Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):532-5. PubMed ID: 12527855
[TBL] [Abstract][Full Text] [Related]
17. Treatment of pituitary tumors: somatostatin.
Tichomirowa MA; Daly AF; Beckers A
Endocrine; 2005 Oct; 28(1):93-100. PubMed ID: 16311415
[TBL] [Abstract][Full Text] [Related]
18. Rationale of pre-surgical medical treatment with somatostatin analogs in acromegaly.
Cappabianca P; Cavallo LM; Esposito F; Romano I; Colao A; de Divitiis E
J Endocrinol Invest; 2003; 26(8 Suppl):55-8. PubMed ID: 15233214
[No Abstract] [Full Text] [Related]
19. Long-term primary medical therapy with somatostatin analogs in acromegaly.
Su DH; Liao KM; Chen HW; Chang TC
J Formos Med Assoc; 2006 Aug; 105(8):664-9. PubMed ID: 16935768
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and limits of somatostatin analogs.
Petersenn S
J Endocrinol Invest; 2005; 28(11 Suppl International):53-7. PubMed ID: 16625846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
